Tocilizumab (Actemra)

References

• Assessment Report For RoActemra [Internet]. 1st ed. London: European Medicines Agency; 2009 [accessed 2017 Jan 3]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000955/WC500054888.pdf
   Google Scholar
• RoACTEMRA [Internet]. F Hoffmann-La Roche Ltd; c2017 [accessed 2017 Jan 2]. http://www.roche.com/products/product-details.htm?productId=30d444d8-7658-469e-9fce-f4de549c00c4
   Google Scholar
• ACTEMRA [Internet]. Genentech USA; c2016 [accessed 2017 Jan 2]. http://www. actemra.com/
   Google Scholar
• Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K. A case of multicentric castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, Tocilizumab. J Korean Med Sci 2010; 25(9):1364-7; PMID:20808682; https://doi.org/10.3346/jkms.2010.25.9.1364
   PubMed Web of Science ®Google Scholar
• RoActemra 20mg/ml Concentrate for Solution for Infusion. Electronic Medicines Compendium; 29/07/16 [Updated 9/8/16; accessed 4/1/17]. Available from: https://www.medicines.org.uk/emc/medicine/22311/SPC/RoActemra+20mg+ml+Concentrate+for+Solution+for+Infusion/
   Google Scholar
• Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, Matsumoto T, Yamamura T, Azuma J, Nishimoto N, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126(4):989-96; PMID:15057738; https://doi.org/10.1053/j.gastro.2004.01.012
   PubMed Web of Science ®Google Scholar
• Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, Fleisher T, Balow JE, Lipsky PE. Tocilizumab in Systemic Lupus Erythematosus: Data on safety, preliminary efficacy, and Impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62(2):542-52; PMID:20112381; https://doi.org/10.1002/art.27221
   PubMed Web of Science ®Google Scholar
• Abisror N, Mekinian A, Lavigne C, Vandenhende MA, Soussan M, Fain O, Club Rhumatismes et Inflammation, and SNFMI. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 2013; 12:1143-9; PMID:23820042; https://doi.org/10.1016/j.autrev.2013.06.019
   PubMed Web of Science ®Google Scholar
• Stone J, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial [abstract]. Arthritis Rheumatol (Hoboken, NJ) 2016; 68(suppl 10)
   Google Scholar
• Hagihara K, Kawase I, Tanaka T, Kishimoto T. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica. J Rheumatol 2010; 37(5):1075-6; PMID:20439532; https://doi.org/10.3899/jrheum.091185
   PubMed Web of Science ®Google Scholar
• Study of Tocilizumab to Treat Polymyalgia Rheumatica - Full Text View - ClinicalTrials.gov [Internet]. [cited 2016 Jul 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01396317
   Google Scholar
• Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C. Treatment of refractory adult-onset still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011; 31(12):1653-6; PMID:21240503; https://doi.org/10.1007/s00296-010-1631-y
   PubMed Web of Science ®Google Scholar
• Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002; 46(12):3388-9; PMID:12483747; https://doi.org/10.1002/art.10620
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nagashima T, Takatori S, Kawahara Y, Yagi M, Iwamoto M, Okazaki H, Minota S. Glucocorticoid and cyclosporine refractory adult onset Still's disease successfully treated with tocilizumab. Clin Rheumatol 2009; 28(4):485-7; PMID:19184270; https://doi.org/10.1007/s10067-009-1097-z
   PubMed Web of Science ®Google Scholar
• Tocilizumab (RoActemra (EU), Actemra (US)) UKMi New Drugs Online Database [Internet]. [cited 2016 Jun 19]. Available from: http://www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID = 4214
   Google Scholar
• Calabrese LH, Rose-John S. “IL-6 biology: implications for clinical targeting in rheumatic disease. Nat Rev Rheumatol 2014; 10(12): 720-727; PMID:25136784; https://doi.org/10.1038/nrrheum.2014.127
   PubMed Web of Science ®Google Scholar
• Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010; 2(5):247-56; PMID:22870451; https://doi.org/10.1177/1759720X10378372
   PubMedGoogle Scholar
• Simpson RJ, Hammacher A, Smith DK, Matthews JM, Ward LD. Interleukin-6: Structure-function relationships. Protein Sci 1997; 6(5):929-55; PMID:9144766; https://doi.org/10.1002/pro.5560060501
   PubMed Web of Science ®Google Scholar
• Kishimoto T. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23:1-21; PMID:15771564; https://doi.org/10.1146/annurev.immunol.23.021704.115806
   PubMed Web of Science ®Google Scholar
• Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci 2012; 122(4):143-59; PMID:22029668; https://doi.org/10.1042/CS20110340
   PubMed Web of Science ®Google Scholar
• Luchtefeld M, Preuss C, Rühle F, Bogalle EP, Sietmann A, Figura S, Müller W, Grote K, Schieffer B, Stoll M. Gp130-dependent release of acute phase proteins is linked to the activation of innate immune signaling pathways. PloS One 2011; 6(5):19427; https://doi.org/10.1371/journal.pone.0019427
   Web of Science ®Google Scholar
• Garbers C, Thaiss W, Jones GW, Waetzig GH, Lorenzen I, Guilhot F, Lissilaa R, Ferlin WG, Grötzinger J, Jones SA, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem 2011; 286(50):42959-70; PMID:21990364; https://doi.org/10.1074/jbc.M111.295758
   PubMed Web of Science ®Google Scholar
• Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012; 8(9):1237-47; PMID:23136552; https://doi.org/10.7150/ijbs.4989
   PubMed Web of Science ®Google Scholar
• Honjo T, Reth M, Radbruch A, Alt F. Molecular Biology of B Cells. Elsevier; 2014
   Google Scholar
• Bondeson J, Wainwright SD, Lauder S, Amos N, Hughes CE. The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. Arthritis Res Ther 2006; 8(6):1; https://doi.org/10.1186/ar2099
   Web of Science ®Google Scholar
• Kimura A, Kishimoto T. IL‐6: Regulator of Treg/Th17 balance. Euro J Immunol 2010; 40(7):1830-5; PMID:20583029; https://doi.org/10.1002/eji.201040391
   PubMed Web of Science ®Google Scholar
• Yoshitake F, Itoh S, Narita H, Ishihara K, Ebisu S. Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways. J Biol Chem 2008; 283(17):11535-40; PMID:18296709; https://doi.org/10.1074/jbc.M607999200
   PubMed Web of Science ®Google Scholar
• Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996; 271(2):736-41; PMID:8557680; https://doi.org/10.1074/jbc.271.2.736
   PubMed Web of Science ®Google Scholar
• Higuchi T, Nakanishi T, Takada K, Matsumoto M, Okada M, Horikoshi H, Suzuki K. A case of multicentric Castleman's disease having lung lesion successfully treated with humanized anti-interleukin-6 receptor antibody, tocilizumab. J Korean Med Sci 2010; 25(9):1364-7; PMID:20808682; https://doi.org/10.3346/jkms.2010.25.9.1364
   PubMed Web of Science ®Google Scholar
• Guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis.pdf [Internet]. [cited 2016 Jun 19]. Available from: http://www.rheumatology.org.uk/includes/documents/cm_docs/2014/b/bsr_bhpr_guideline_for_the_use_of_intravenous_tocilizumab_in_the_treatment_of_adult_patients_with_rheumatoid_arthritis.pdf
   Google Scholar
• Lally F, Smith E, Filer A, Stone MA, Shaw JS, Nash GB, Buckley CD, Ed Rainger G. A novel mechanism of neutrophil recruitment in a coculture model of the rheumatoid synovium. Arthritis Rheum 2005; 52(11):3460-9; https://doi.org/10.1002/art.21394
   PubMed Web of Science ®Google Scholar
• Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012; 51(4 Suppl):v3-11; PMID:22718924; https://doi.org/10.1093/rheumatology/kes113
   PubMed Web of Science ®Google Scholar
• Reiff A. Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab-the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment. Biol Ther 2012; 2(1):1-2; PMID:24392296; https://doi.org/10.1007/s13554-012-0001-6
   PubMedGoogle Scholar
• Caparbo VF, Prada F, Silva CA, Regio PL, Pereira RM. Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts “in vitro.” Clin Rheumatol 2009; 28(1):71-7; PMID:18685881; https://doi.org/10.1007/s10067-008-0985-y
   PubMed Web of Science ®Google Scholar
• GUIDELINE ON DEVELOPMENT, PRODUCTION, CHARACTERISATION AND SPECIFICATIONS FOR MONOCLONAL ANTIBODIES AND RELATED PRODUCTS [Internet]. 1st ed. London: European Medical Agency; 2009 [cited 18 August 2016]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003074.pdf
   Google Scholar
• ICH Topic Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products [Internet]. 1st ed. London: European Medical Agency; 1999 [cited 18 August 2016]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002824.pdf
   Google Scholar
• ICH Topic Q5E Comparability of Biotechnological/Biological products [Internet]. London: European Medicines Agency; ࣮ EMEA 2006 [accessed 2017 Jan 3]. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002805.pdf
   Google Scholar
• Vezér B, Buzás Z, Sebeszta M, Zrubka Z. Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents. Curr Med Res Opin 2016; 32(5):829-34; https://doi.org/10.1185/03007995.2016.1145579
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50(6):1761-9; https://doi.org/10.1002/art.20303
   PubMed Web of Science ®Google Scholar
• Sebba A. Tocilizumab: the first interleukin-6-receptor inhibitor. Am J Health Syst Pharm 2008; 65:1413-18; PMID:18653811; https://doi.org/10.2146/ajhp070449
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, Van Vollenhoven R, Sanchez A, Alecock E, Lee J, Kremer J. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67(11):1516-23; PMID:18625622; https://doi.org/10.1136/ard.2008.092932
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, Woodworth T, Alten R, OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008; 371(9617):987-97; https://doi.org/10.1016/S0140-6736(08)60453-5
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, Siri DA, Tomšič M, Alecock E, Woodworth T, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010; 69(01):88-96; PMID:19297346; https://doi.org/10.1136/ard.2008.105197
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, Ambs P, Fleischmann R. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011; 63(3):609-21; https://doi.org/10.1002/art.30158
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, Woodworth T, Gomez-Reino JJ. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheumat 2008; 58(10):2968-80; https://doi.org/10.1002/art.23940
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, Hall S, Leszczynski P, Feldman D, Rangaraj MJ, Roane G, Ludivico C, Lu P, et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 2014; 73(1):69-74; PMID:23904473; https://doi.org/10.1136/annrheumdis-2013-203523
   PubMed Web of Science ®Google Scholar
• Kivitz A, Olech E, Borofsky MA, Zazueta BM, Navarro-Sarabia F, Radominski SC, Merrill JT, Pei J, Rowell L, Nasmyth-Miller C, et al. The efficacy and safety of tocilizumab subcutaneous Q2w and following escalation from Q2w to Qw therapy in combination with traditional dmards in patients with moderate to severe rheumatoid arthritis at 96 weeks. Arthritis Rheumatol 2014; 66:S1076-7
   Web of Science ®Google Scholar
• Chaitow J, De Benedetti F, Brunner H, Ruperto N, Allen R, Murray K, Schneider R, Woo P, Wright S, Kenwright A, et al. Tocilizumab in patients with systemic juvenile idiopathic arthritis: Efficacy data from the placebo-controlled 12-week part of the phase III tender trial. Intern Med J 2011; 41:32-; https://doi.org/10.1111/j.1445-5994.2011.02489.x
   Web of Science ®Google Scholar
• Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis 2014; 74(6):1110-7; PMID:24834925; https://doi.org/10.1136/annrheumdis-2014-205351
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68(10):1580-4; PMID:19019888; https://doi.org/10.1136/ard.2008.092866
   PubMed Web of Science ®Google Scholar
• Farah Z, Ali S, Price-Kuehne F, Mackworth-Young CG. Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years. Biologics 2016; 10:59
   PubMedGoogle Scholar
• De Benedetti F, Brunner H, Ruperto N, Cuttica R, Malattia C, Schneider R, Woo P, Eleftheriou D, Baildam E, Burgos-Vargas R, et al. Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data. Pediatric Rheumatol 2012; 10(1):1; PMID:22222048; https://doi.org/10.1186/1546-0096-10-1
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Goto H, Hirao K, Nakajima A, Origasa H, Tanaka K, Tomobe M, Totsuka K. Longterm safety of tocilizumab: results from 3 years of followup postmarketing surveillance of 5573 patients with rheumatoid arthritis in Japan. J Rheumatol 2015; 42(8):1368-75; PMID:26034149; https://doi.org/10.3899/jrheum.141210
   PubMed Web of Science ®Google Scholar
• Genovese MC, Rubbert-Roth A, Smolen JS, Kremer J, Khraishi M, Gómez-Reino J, Sebba A, Pilson R, Williams S, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013; 40(6):768-80; PMID:23457383; https://doi.org/10.3899/jrheum.120687
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Modern Rheumatol 2010; 20(3):222-32; PMID:20221663; https://doi.org/10.3109/s10165-010-0279-5
   PubMed Web of Science ®Google Scholar
• Klein K, Scholl JH, Vermeer NS, Broekmans AW, Van Puijenbroek EP, De Bruin ML, Stolk P. Traceability of Biologics in The Netherlands: An Analysis of Information-Recording Systems in Clinical Practice and Spontaneous ADR Reports. Drug Saf 2016; 39(2): 185-92; PMID:26719190; https://doi.org/10.1007/s40264-015-0383-8
   PubMed Web of Science ®Google Scholar
• Actemra, Highlights of prescribing Information [Internet]. Genentech; c2013 [accessed 2017 Jan 3]. https://www.gene.com/download/pdf/actemra_prescribing.pdf
   Google Scholar
• RoActemra 162 mg Solution for Injection in Pre-Filled Syringe. Electronic Medicines Compendium; 29/07/16 [Updated 9/8/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/28809/
   Google Scholar
• Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2014; 66(3):344-54; PMID:23983039; https://doi.org/10.1002/acr.22110
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Fukui S, Umeda M, Nishino A, Nakashima Y, Suzuki T, Horai Y, Nonaka F, Okada A, Koga T, et al. Evaluation of switching from intravenous to subcutaneous formulation of tocilizumab in patients with rheumatoid arthritis. Modern Rheumatol 2016; 26(5):662-666; PMID:26708444; https://doi.org/10.3109/14397595.2015.1129692
   PubMed Web of Science ®Google Scholar
• Remicade 100 mg powder for concentrate for solution for infusion. Electronic Medicines Compendium; 9/06/16 [Updated 21/7/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/3236
   Google Scholar
• Humira 40 mg/0.4 ml Pre-filled Syringe and Pre-filled Pen. Electronic Medicines Compendium; 12/12/16 [Updated 30/12/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/31860
   Google Scholar
• Enbrel 50 mg solution for injection in pre-filled pen. Electronic Medicines Compendium; 1/04/16 [Updated 6/5/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/22143
   Google Scholar
• Simponi 100 mg solution for injection. Electronic Medicines Compendium; 13/10/16 [Updated 11/11/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/28316
   Google Scholar
• Cimzia 200 mg solution for injection in pre-filled syringe. Electronic Medicines Compendium; 01/12/16 [Updated 20/12/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/22323
   Google Scholar
• Mabthera 100 mg and 500 mg Concentrate for Solution for Infusion. Electronic Medicines Compendium; 26/05/16 [Updated 8/6/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/2570
   Google Scholar
• Kineret 100 mg solution for injection in a pre-filled syringe. Electronic Medicines Compendium; 28/01/16 [Updated 31/03/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/23104
   Google Scholar
• ORENCIA 250 mg powder for concentrate for solution for infusion. Electronic Medicines Compendium; 01/08/16 [Updated 1/9/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/19714
   Google Scholar
• Ilaris 150 mg powder for solution for injection. Electronic Medicines Compendium; 1/08/16 [Updated 10/8/16; accessed 4/1/17]. Available from: http://www.medicines.org.uk/emc/medicine/22718
   Google Scholar
• James K, Bell GT. Human monoclonal antibody production. Current status and future prospects. J Immunol Methods 1987; 100(1-2):5-40; PMID:3298441; https://doi.org/10.1016/0022-1759(87)90170-0
   PubMed Web of Science ®Google Scholar
• Hwang WY, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36(1):3-10; PMID:15848070; https://doi.org/10.1016/j.ymeth.2005.01.001
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, Van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Klearman M, Musselman D, Agarwal S, Green J, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013; 381(9877):1541-50; https://doi.org/10.1016/S0140-6736(13)60250-0
   PubMed Web of Science ®Google Scholar
• Veronese FM, Mero A. The Impact of PEGylation on Biological Therapies. Biodrugs 2008; 22(5):315-29; PMID:18778113; https://doi.org/10.2165/00063030-200822050-00004
   PubMed Web of Science ®Google Scholar
• Goel N, Stephens S. Certolizumab Pegol. MAbs 2010; 2(2):137-47; PMID:20190560; https://doi.org/10.4161/mabs.2.2.11271
   PubMed Web of Science ®Google Scholar
• Flint J, Panchal S, Hurrell A, Van de Venne M, Gayed M, Schreiber K, Arthanari S, Cunningham J, Flanders L, Moore L, et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology 2016; 55(9):1693-7; PMID:26750124; https://doi.org/10.1093/rheumatology/kev404
   PubMed Web of Science ®Google Scholar
• RoActemra 162 mg Solution for Injection in Pre-Filled Syringe. Electronic Medicines Compendium; 29/07/16 [Updated 9/8/16; accessed 5/1/17]. Available from: https://www.medicines.org.uk/emc/medicine/28809
   Google Scholar
• ORENCIA 125 mg solution for injection (pre-filled syringe). Electronic Medicines Compendium; 01/08/16 [Updated 1/9/16; accessed 5/1/17]. Available from: https://www.medicines.org.uk/emc/medicine/27216
   Google Scholar
• Huynh TK, Østergaard A, Egsmose C, Ole Rintek M. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence 2014; 8:93-9
   PubMed Web of Science ®Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7527 patients. Arthritis Rheum 2003; 48:2750-62; PMID:14558079; https://doi.org/10.1002/art.11439
   PubMed Web of Science ®Google Scholar
• Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res 2011; 3:29-36; PMID:21935330; https://doi.org/10.2147/CEOR.S12494
   PubMedGoogle Scholar
• Leffers HCB, Østergaard M, Glintborg B, Krogh NS, Tarp U, Lorenzen T, Hansen A, Dreyer L, Hetland ML. Three-year drug survival and effectiveness of abatacept and tocilizumab in patients with rheumatoid arthritis treated in routine care. Results from the Nationwide Danish Danbio Registry. Arthritis Rheum 2013; 65(Suppl 10)
   Google Scholar
• Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IB, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, et al. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010; 62(1):22-32; PMID:20039405; https://doi.org/10.1002/art.27227
   PubMed Web of Science ®Google Scholar
• Hishitani Y, Ogata A, Shima Y, Hirano T, Ebina K, Kunugiza Y, Shi K, Narazaki M, Hagihara K, Tomita T, et al. Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis. Scand J Rheumatol 2013; 42(4):253-9; PMID:23470089; https://doi.org/10.3109/03009742.2012.762037
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; 16(2):CD008794
   Google Scholar
• Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003; 48(8):2122-7; PMID:12905464; https://doi.org/10.1002/art.11137
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Nishimoto N, Yamanaka H. Experience with Mycobacterium tuberculosis infection reported in the tocilizumab worldwide RA safety database. Ann Rheum Dis 2009; 68(Suppl 3):567
   Google Scholar
• Gout T, Ostör AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011; 30(11):1471-4; PMID:21833686; https://doi.org/10.1007/s10067-011-1827-x
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, Takei S, Tanaka Y, Sano Y, Yaguramaki H, et al. Effectiveness and safety of tocilizumab: postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan. J Rheumatol 2014; 41(1):15-23; PMID:24187110; https://doi.org/10.3899/jrheum.130466
   PubMed Web of Science ®Google Scholar
• Daïen CI, Duny Y, Barnetche T, Daurès J, Combe B, Morel J. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann Rheum Dis 2012; 71:862-8; PMID:22267329; https://doi.org/10.1136/annrheumdis-2011-201148
   PubMed Web of Science ®Google Scholar
• Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010; 39(6):425-41; PMID:20223500; https://doi.org/10.1016/j.semarthrit.2009.12.002
   PubMed Web of Science ®Google Scholar
• Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Márquez-Fernández E, Ramos-Báez JJ. Indirect comparison of biological treatments in refractory rheumatoid arthritis. J Clin Pharm Ther 2012; 37(3):301-7; PMID:21831256; https://doi.org/10.1111/j.1365-2710.2011.01292.x
   PubMed Web of Science ®Google Scholar
• Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, Bombardier C, Keystone E. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011; 70(2):266-71; PMID:21097801; https://doi.org/10.1136/ard.2010.132134
   PubMed Web of Science ®Google Scholar
• Jones G, Darian-Smith E, Kwok M, Winzenberg T. Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate? Biologics 2012; 6:155-61
   PubMedGoogle Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Murata N, van der Heijde D, Kishimoto T. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007; 66(9):1162-7; PMID:17485422; https://doi.org/10.1136/ard.2006.068064
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013; 72(1):43-50; PMID:22562983; https://doi.org/10.1136/annrheumdis-2011-201282
   PubMed Web of Science ®Google Scholar
• Sibilia J, Graninger W, Ostor A, et al. Comparison of tocilizumab as monotherapy or with add-on DMARDS in patients with rheumatoid arthritis and an inadequate response to previous treatments: ACT-SURE results. Ann Rheum Dis 2011; 70:466
   Google Scholar
• `Weinblatt ME, Kremer J, Cush J, Rigby W, Teng LL, Devenport J, Singh N, Lepley D, Genovese MC. Tocilizumab as monotherapy or in combination with nonbiologic DMARDs: 24-week results of an open-label, clinical practice study (ACT-STAR). Arthritis Care Res 2013; 65(3):362-71; https://doi.org/10.1002/acr.21847
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Panayi GS. Interleukin-6 in the serum of patients with polymyalgia rheumatica and giant cell arteritis. Br J Rheumatol 1990; 29:456-8; PMID:2124160; https://doi.org/10.1093/rheumatology/29.6.456
   PubMedGoogle Scholar
• Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43:1041-8; PMID:10817557; https://doi.org/10.1002/1529-0131(200005)43:5%3c1041::AID-ANR12%3e3.0.CO;2-7
   PubMed Web of Science ®Google Scholar
• Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, Bütikofer L, Seitz M, Reichenbach S. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387:1921-27; PMID:26952547; https://doi.org/10.1016/S0140-6736(16)00560-2
   PubMed Web of Science ®Google Scholar
• Evans J, Steel L, Borg F, Dasgupta B. Long-term efficacy and safety of tocilizumab in giant cell arteritis and large vessel vasculitis. RMD Open 2016; 2:e000137; PMID:26819753; https://doi.org/10.1136/rmdopen-2015-000137
   PubMed Web of Science ®Google Scholar
• Devauchelle V, Berthelot JM, Cornec D. Efficacy and safety of tocilizumab as first line therapy in patients with recent Polymyalgia Rheumatica (PMR): results of the first longitudinal prospective study (Tenor). Ann Rheum Dis 2015; 74:526; PMID:24347569; https://doi.org/10.1136/annrheumdis-2015-eular.2727
   PubMed Web of Science ®Google Scholar
• SIRRESTA study. ClinicalTrials.gov Identifier: NCT02531633 (available from https://clinicaltrials.gov/ct2/show/NCT02531633?term=sirukumab&rank=1)
   Google Scholar